DemeRx IB, Inc. CEO Deborah Mash joined Proactive New York to discuss the group's joint venture with Atai Life Sciences (NASDAQ:ATAI), focused on developing ibogaine to treat opioid use disorder.
Mash says the group has recently dosed its first patient with an oral form of ibogaine DMX-1002 in a Phase 1/2a clinical trial at the Manchester clinical unit of MAC Clinical Research in the UK, in order to precisely define the therapeutic safety margin. Phase 1 data is expected by early 2022.